Hohl Benjamin (CIK 1882764) reported 38 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-21). Recent activity: Buy ELVN (3,982 shares), Sell ELVN (3,535 shares), Sell ELVN (2,194 shares), Sell ELVN (289 shares), Sell ELVN (4,630 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 3,982 | $59,133 |
| 2026-09-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 3,535 | $176,851 |
| 2026-09-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 2,194 | $111,270 |
| 2026-09-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 289 | $14,881 |
| 2026-08-19 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 4,630 | $270,168 |
| 2026-08-19 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 1,388 | $82,383 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 1,072 | $2,659 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 324 | $16,191 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 369 | $18,997 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 2,564 | $134,143 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 2,638 | $140,823 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 123 | $6,626 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 6,018 | $14,925 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 1,379 | $59,007 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 3,401 | $149,168 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 1,238 | $55,400 |
| 2026-03-10 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 10,000 | $295,800 |
| 2026-02-17 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 25,000 | $0 |
| 2025-12-23 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 13,000 | $32,240 |
| 2025-10-01 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 3,250 | $8,060 |
| 2025-10-01 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $66,300 |
| 2025-08-29 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 3,250 | $8,060 |
| 2025-08-29 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $67,048 |
| 2025-07-30 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 3,250 | $8,060 |
| 2025-07-30 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 3,185 | $65,133 |
来源：SEC Form 4 申报文件 · 截至 2026-09-21